Navigation Links
Gene mutation improves leukemia drug's effect

COLUMBUS, Ohio Gene mutations that make cells cancerous can sometimes also make them more sensitive to chemotherapy. A new study led by cancer researchers at Ohio State University shows that a mutation present in some cases of acute leukemia makes the disease more susceptible to high doses of a particular anticancer drug.

The findings, from a Cancer and Leukemia Group B clinical cooperative group study led by Dr. Clara D. Bloomfield, an internationally known AML specialist at the Ohio State University Comprehensive Cancer Center, could change how doctors manage these patients.

The research is published online in the June 16 issue of the Journal of Clinical Oncology with an accompanying editorial.

The retrospective study shows that people with acute myeloid leukemia (AML) whose leukemic cells have mutations in the RAS gene are more likely to be cured when treated after remission with high doses of the drug cytarabine.

It also suggests that testing for RAS mutations might help doctors identify which AML patients should receive high-dose cytarabine as their post-remission therapy.

"This appears to be the first example in AML of a mutation in an oncogene that favorably modifies a patient's response to the dose of a routinely used chemotherapeutic drug," Bloomfield says.

"If confirmed, AML patients in the future will likely be screened for RAS mutations, and those who have one may get high-dose cytarabine for post-remission therapy rather than a stem-cell transplant."

Typically, people with newly diagnosed AML are treated first with drugs intended to drive the disease into complete remission, Bloomfield says. When that is achieved, patients are given additional chemotherapy, such as high-dose cytarabine, or more aggressive therapy, such as a stem cell transplant, to prevent relapse and to cure the malignancy.

But high-dose cytarabine is the better therapy for some patients, and the findings of this study may enable doctors to identify those individuals.

The research analyzed the outcome of 185 AML patients age 60 or less who had achieved complete remission following initial therapy. Thirty-four of the patients (18 percent) had mutations in the RAS gene, and of these, 22 received high-dose cytarabine and 12 received the drug at low dose.

The high-dose patients with RAS mutations had the lowest relapse rate 45 percent experienced disease recurrence after an average 10-year follow-up compared with 68 percent for those with normal RAS genes.

"That means fifty-five percent of patients with RAS mutations were cured compared with 32 percent of high-dose patients with normal RAS," Bloomfield says.

Of patients who received low doses of the drug, all those with the mutations relapsed, as did 80 percent of those with normal RAS genes.

"These data strongly suggest that mutations in RAS influence the response of AML patients to high-dose cytarabine, and they support the use of these mutations as biomarkers for this therapy," says Bloomfield, who is also a Distinguished University Professor, the William G. Pace III Professor in Cancer Research and an OSU Cancer Scholar.


Contact: Darrell E. Ward
Ohio State University Medical Center

Related medicine news :

1. Gene Mutations May Cause Rare Neonatal Diabetes
2. Gene Mutation Linked to Parkinsons Disease
3. Research shows how genetic mutation causes epilepsy in infants
4. Gene Mutation Key to Infertility in Male Mice
5. Overlooked Mutation Can Spur HIV Drug Resistance
6. OHSU Cancer Institute researcher discovers what fuels certain cancer mutation
7. Breast cancer gene mutation more common in Hispanic, young black women, Stanford/NCCC study finds
8. BRCA1 Mutation Prevalent Among Hispanic, Younger Black Women
9. Ashkenazi ovarian cancer patients with BRCA mutations live longer than those with normal gene
10. BRCA Mutations Dont Raise Breast Cancer Risk Equally
11. Genetic Mutations Boost Prostate Cancer Risk
Post Your Comments:
(Date:11/25/2015)... Livonia, MI (PRWEB) , ... November 25, 2015 , ... ... at Presence Resurrection Medical Center (RMC) in Chicago, IL, UV Angel is evaluating the ... the medical and surgical intensive care units (totaling 30 beds) from May 2014 through ...
(Date:11/25/2015)... ... November 25, 2015 , ... Today, Mothers Against Drunk ... roadways has dropped below 10,000 for the first time since 2011. In 2014, there ... According to data released by the National Highway Traffic Safety Administration (NHTSA), 32,675 people ...
(Date:11/25/2015)... ... November 25, 2015 , ... In honor of ... Pioneers, individuals and groups responsible for advancing care for pulmonary hypertension (PH) patients ... by the public, will receive special recognition throughout 2016 as part of PHA’s ...
(Date:11/25/2015)... ... November 25, 2015 , ... Privately owned Contract ... significant expansion of its current state of the art research, development and manufacturing ... to increase its manufacturing capacity as well as to support its clients’ growing ...
(Date:11/25/2015)... ... November 25, 2015 , ... Many people know of the common symptoms of ... and dry skin. But many people who find their cholesterol levels and weight are ... their thyroid, especially if they don’t have any of the other symptoms. , Thyroid ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015  ARKRAY USA ... continues to provide evidence demonstrating the accuracy of its ... Congress on Insulin Resistance, Diabetes and Cardiovascular Disease in ... both the Company,s GLUCOCARD ® 01 meter and ... accuracy requirements. The ability to accurately measure glucose levels ...
(Date:11/25/2015)... 25, 2015 Kitov Pharma ... KTOV), a biopharmaceutical company focused on the development of ... conditions, today announced the closing of its previously announced ... ADSs ), each representing 20 ordinary shares of the ... The ADSs and warrants were issued in a fixed ...
(Date:11/25/2015)... SAN DIEGO , Nov. 25, 2015  Trovagene, ... molecular diagnostics, today announced that Chief Executive Officer Antonius ... at the 27 th Annual Piper Jaffray Healthcare ... Conference at the New York Palace Hotel in ... 2015 at 1:30 p.m. EST. Mr. Schuh will be ...
Breaking Medicine Technology: